Every material Form 8-K MADRIGAL PHARMACEUTICALS, INC. has filed with the SEC since July 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Madrigal Pharmaceuticals reported third-quarter 2026 results, with net revenues of $431.3 million, up 50% from $287.3 million a year earlier, driven by U.S. demand for Rezdiffra. The company reported net income of $55.4 million, or $1.83 per diluted share, compared with a net loss of $114.2 million in the prior-year period.
Q3 2026 net revenues were $431.3 million, up 50% from $287.3 million in Q3 2025.
Q3 2026 net income was $55.4 million, or $1.83 per diluted share, versus a net loss of $114.2 million, or $4.01 per share, a year earlier.
Cash, cash equivalents, restricted cash and marketable securities were $961.8 million as of Sept. 30, 2026, compared with $988.6 million on Dec. 31, 2025.
Cost of sales rose to $37.8 million from $18.1 million, mainly due to higher royalties payable to Roche; the prior-year R&D figure included a one-time $117.3 million business development expense.
Madrigal Pharmaceuticals expanded its Board from eight to nine members on August 11, 2026, and elected John C. Reed, M.D., Ph.D., to fill the new seat. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson, and his board appointment is a governance change with no financial results reported in the filing.
Board expanded from eight to nine members; Reed elected effective August 11, 2026 as a Class II director, term expiring at the 2027 annual meeting.
Reed receives a $50,000 annual cash retainer plus $10,000 annually for Science and Technology Committee service.
Initial equity grant valued at $675,000, split 50% stock options and 50% restricted stock units under the 2026 Stock Plan.
Madrigal Pharmaceuticals reported second-quarter 2026 net revenue of $364.3 million, up 71% from $212.8 million a year earlier, driven by higher U.S. demand for Rezdiffra. The net loss widened to $57.9 million, or $1.99 per share, from $42.3 million, or $1.50 per share, with a $25.0 million one-time upfront business development expense included. Operating expenses rose to $420.6 million, and cash and marketable securities totaled $838.9 million as of June 30, 2026.
Q2 2026 net revenue was $364.3 million, up 71% from $212.8 million in the prior-year quarter.
Q2 2026 net loss was $57.9 million, or $1.99 per share, versus $42.3 million, or $1.50 per share, a year earlier.
The net loss included a $25.0 million one-time upfront business development expense, or $0.86 per share.
Cash, cash equivalents, restricted cash and marketable securities were $838.9 million at June 30, 2026, versus $988.6 million at Dec. 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MADRIGAL PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →